DICE Therapeutics, Inc. (NASDAQ:DICE – Get Free Report) has been assigned an average recommendation of “Hold” from the thirteen brokerages that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among […]
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 4,360,000 shares, a decrease of 10.7% from the July 15th total of 4,880,000 shares. Approximately 10.4% of the company’s stock are short sold. […]
DICE Therapeutics (NASDAQ:DICE – Get Free Report) is scheduled to announce its earnings results after the market closes on Tuesday, August 15th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. DICE Therapeutics (NASDAQ:DICE – Get Free Report) last announced its earnings results on Thursday, May 11th. The company reported […]
Guggenheim cut shares of DICE Therapeutics (NASDAQ:DICE – Get Rating) from a buy rating to a neutral rating in a report published on Wednesday morning, The Fly reports. DICE has been the topic of several other reports. Cowen assumed coverage on shares of DICE Therapeutics in a research note on Wednesday, March 1st. They set […]
SVB Securities cut shares of DICE Therapeutics (NASDAQ:DICE – Get Rating) from an outperform rating to a market perform rating in a report issued on Wednesday, The Fly reports. A number of other brokerages have also recently weighed in on DICE. Wells Fargo & Company upped their price objective on shares of DICE Therapeutics from […]